Terracciano L M, Glatz K, Mhawech P, et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases[J]. Am J Surg Pathol,2003,27:1302-12.
[2]
Choi W K, Cho D H, Yim C Y, et al. Primary hepatoid carcinoma of the ovary: a case report and review of the literature[J]. Medicine(Baltimore), 2020,99(19):e20051.
[3]
Lei L, Yang L, Xu YY, et al. Hepatoid adenocarcinoma of the lung: an analysis of the surveil-lance, epidemiology, and end results(SEER) database[J].Open Med(Wars), 2021,16(1): 169-174.
[4]
Ishikur H, Fukasawa Y, Ogasawara K, et al. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report[J].Cancer,1985,56(4):840-848.
[5]
Vardaman C. Clear cell carcinomas of the gallbladder and extrahepatic bile ducts[J].Am J Surg Pathol,1995,19(1):91-99.
[6]
Su J S, Chen Y T, Wang R C, et al. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review[J]. World J Gastroentero, 2013,19(3): 321-327.
Metzgeroth G, Strobel P, Baumbusch T,et al. Hepatoid adenocarcinoma review of the literature illustrated by a rare case originating in the peritoneal cavity[J].Onkologie,2010,33(5):263-269.
[9]
Lin H J, Hsieh Y H, Fang W L, et al. Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer[J]. Curr Oncol,2014,21(3):e394-e399.
[10]
Qian X, Zhou D, Gao B, et al. An alpha-fetoprotein-negative hepatoid adenocarcinoma of the gallbladder with squamous differentiation[J].Hepatobil Surg Nutr,2020,9(1):116-118.
[11]
Ayub A, Nunez L O, Booth A, et al. Pulmonary hepatoid adenocarcinoma[J].Thorac Cardiovasc Surg, 2019,158(4):e139-e140.
[12]
Kinjo T, Taniguchi H, Kushima R, et al. Hisologic and immunohistochemical analyses of α-fetoprotein-producing cancer of the stomach[J].Am J Surg Pathol,2012,36(1):56-65.
Simmet V, Noblecourt M, Lizee T, et al. Chemotherapy of metastatic hepatoid adenocarcinoma: literature review and two case reports with cisplatin etoposide[J]. Oncol Lett,2018,15(1):48-54.
[15]
Arakawa Y, Tamura M, Aiba K, et al. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report[J]. Oncol Lett, 2017,14(3):3039-3042.
[16]
Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types[J].Clin Pathol, 2018,71(7):600-607.
[17]
Wang Y, Sun L, Li Z, et al. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features[J]. Gastric Cancer,2019,22(6):1-10.
[18]
Søreide J A. Therapeutic approaches to gastric hepatoid adenocarcinoma:current perspec-tives[J]. Ther Clin Risk Manag, 2019, 23(15):1469-1477.
2023, Vol. 34 
